Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group

The standard of care for patients with advanced cervical cancer (ACC) includes platinum-based chemotherapy. The concept of platinum sensitivity is a major prognostic factor for patients with ovarian cancer. The aim of this study was to validate the applicability of the platinum sensitivity concept t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2020-11, Vol.9 (11), p.3646
Hauptverfasser: de Foucher, Tiphaine, Hennebert, Cecile, Dabi, Yohan, Ouldamer, Lobna, Lavoué, Vincent, Dion, Ludivine, Canlorbe, Geoffroy, Bolze, Pierre Adrien, Golfier, François, Akladios, Cherif, Lecointre, Lise, Kerbage, Yohan, Collinet, Pierre, Bricou, Alexandre, Carcopino, Xavier, Huchon, Cyrille, Raimond, Emilie, Graesslin, Olivier, Owen, Clémentine, Touboul, Cyril, Ballester, Marcos, Darai, Emile, Bendifallah, Sofiane
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The standard of care for patients with advanced cervical cancer (ACC) includes platinum-based chemotherapy. The concept of platinum sensitivity is a major prognostic factor for patients with ovarian cancer. The aim of this study was to validate the applicability of the platinum sensitivity concept to ACC patients, and to estimate its prognostic interest in terms of overall survival (OS) and pattern of recurrence (location, timing). Data of women with histologically proven FIGO 2019 stages IB3–IV ACC, treated between May 2000 and November 2017 with platinum-based regimens, were retrospectively abstracted from 12 institutions from the FRANCOGYN Group. Respective 3-year OSs were 52% (95% CI: 40.8%–66.8%), 21.6% (95% CI: 12.6%–37.2%), and 14.6% (95% CI: 4.2%–50.2%), in case of recurrence
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm9113646